Novartis (NOVN.SW) ends SIX at CHF118.70 on Feb 04 2026: earnings set the tone

NOVN.SW stock closed on the SIX at CHF118.70 on 04 Feb 2026 after an earnings-related session that pushed the shares higher. The market priced in a modest upside as volume reached 5,794,934 shares, above the 50-day average of 2,967,625. Key numbers: EPS 5.65, PE 20.69, and dividend per share 4.51 CHF. Today’s close follows Novartis’s results and commentary that traders parsed for 2026 guidance and Sandoz margin recovery signals.

Earnings snapshot: NOVN.SW stock results and market reaction

Novartis reported results that the market treated as broadly constructive, lifting the share price to a day high of CHF120.08 before settling at CHF118.70. One clear market reaction was higher volume at 5,794,934 shares, a relative volume of 1.14, indicating above-normal activity. The company’s EPS of 5.65 and trailing PE near 20.69 suggest the stock is priced for steady earnings rather than rapid re-rating.

Business drivers: Innovative Medicines and Sandoz impact on NOVN.SW stock

Novartis’s two-segment structure remains central to the earnings story: Innovative Medicines drives higher-margin growth while Sandoz adds volume and recovery potential. Management highlighted R&D progress in ophthalmology and inclisiran partnerships as revenue catalysts. Investors should watch Sandoz margin improvement and topline growth as drivers of the NOVN.SW stock outlook.

Valuation and ratios: what the numbers say about NOVN.SW stock

Novartis trades at a price-to-earnings ratio around 20.69 with price-to-book near 6.62 and price-to-sales about 5.13, reflecting premium valuation versus many peers. Return on equity is 34.12%, and free cash flow yield is roughly 6.33%. The current dividend per share is 4.51 CHF, implying a yield near 2.99% at today’s price. These metrics show a blend of growth and income characteristics priced at a premium to the Swiss healthcare sector average PE of 34.55.

Technical and trading signals for NOVN.SW stock

Momentum indicators show intensity: RSI is 74.23 (overbought), MACD histogram is 0.53, and ADX reads 22.67, signalling a strong trend but short-term stretch. The 50-day average price is 110.40, and the 200-day average is 101.18, both below the current price, supporting a bullish medium-term bias. Traders should note higher implied volatility and elevated MFI at 71.54.

Meyka AI grade & forecast for NOVN.SW stock

Meyka AI rates NOVN.SW with a score out of 100: 74.39 / 100, Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly level of CHF123.14, a quarterly level of CHF111.57, and a yearly level of CHF108.32. These projections imply a short-term upside to CHF123.14 (+3.74% vs CHF118.70) and a 12-month conservative view slightly below today’s price. Forecasts are model-based projections and not guarantees.

Risk and opportunity: analysts’ focus for NOVN.SW stock

Opportunities: pipeline readouts, Sandoz margin recovery, and inclisiran commercialization could drive upside. Risks: pricing pressure in generics, regulatory setbacks, and current ratio under 1.0 suggesting working-capital tightness. Market-cap sits near CHF224.27 billion, which means company moves can influence sector positioning in Swiss healthcare.

Final Thoughts

Key takeaways for NOVN.SW stock: Novartis closed at CHF118.70 on SIX on 04 Feb 2026 after earnings commentary that the market treated as constructive. The company offers a mix of stable cash flow and pipeline optionality, trading at PE 20.69 and yielding roughly 2.99% in dividends. Technically, the stock shows short-term overbought readings but remains above the 50-day and 200-day averages, supporting a medium-term bullish view. Meyka AI’s forecast model projects a near-term level of CHF123.14, implying +3.74% upside versus today’s price; longer horizon models show incremental upside to CHF133.35 over five years. These model outputs and the B+ (74.39/100) Meyka grade reflect balanced upside potential against operational and pricing risks. For investors, position sizing should reflect Novartis’s sector role, dividend income goals, and the company’s premium valuation. For more data and live updates see our Novartis page and the market coverage linked below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.